Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 ADXS-HPV: a therapeutic Listeria vaccination targeting cervical cancers expressing the HPV E7 antigen.

Literature DB >> 25483687

ADXS-HPV: a therapeutic Listeria vaccination targeting cervical cancers expressing the HPV E7 antigen.

Abstract

Listeria monocytogenes is a bacterium that can be genetically modified to express fusion proteins with antigens specific to certain cancer models. This technology has been harnessed to develop ADXS11-001, a vaccine that aims to elicit an immune response against human papillomavirus (HPV) oncoprotein E7. Pre-clinical studies assessing the efficacy of recombinant Listeria vaccination targeting this same oncoprotein have consistently demonstrated successful reduction of in vivo tumor burden among animal cancer models. Several clinical trials are underway to assess the efficacy of ADXS11-001 in eliciting both immune and clinical responses against HPV-related human cervical, oropharyngeal and anal cancers.

Entities: Disease Species

Keywords: ADXS11-001; FDA, Food and Drug Administration; GOG, Gynecologic Oncology Group; HPV, human papillomavirus; LLO, listeriolysin O; Listeria monocytogenes; Lm, Listeria monocytogenes; MHC, major histocompatibility complex; OPSCC, oropharyngeal cancer; PLC, phospholipase C; VLP, virus like protein; cervical cancer; human papillomavirus; immunotherapy

Mesh：

Substances：

Year: 2014 PMID： 25483687 PMCID： PMC4514130 DOI： 10.4161/hv.34378

Source DB: PubMed Journal: Hum Vaccin Immunother ISSN： 2164-5515 Impact factor: 3.452

36 in total

1. Development of a live and highly attenuated Listeria monocytogenes-based vaccine for the treatment of Her2/neu-overexpressing cancers in human.

Authors: V Shahabi; M M Seavey; P C Maciag; S Rivera; A Wallecha
Journal: Cancer Gene Ther Date: 2010-08-20 Impact factor: 5.987

2. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive.

Authors: L Muderspach; S Wilczynski; L Roman; L Bade; J Felix; L A Small; W M Kast; G Fascio; V Marty; J Weber
Journal: Clin Cancer Res Date: 2000-09 Impact factor: 12.531

3. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16.

Authors: G R Gunn; A Zubair; C Peters; Z K Pan; T C Wu; Y Paterson
Journal: J Immunol Date: 2001-12-01 Impact factor: 5.422

Review 4. Regulation of Listeria virulence: PrfA master and commander.

Authors: Aitor de las Heras; Robert J Cain; Magdalena K Bielecka; José A Vázquez-Boland
Journal: Curr Opin Microbiol Date: 2011-03-08 Impact factor: 7.934

5. Targeting tumor vasculature with novel Listeria-based vaccines directed against CD105.

Authors: Laurence M Wood; Zhen-Kun Pan; Patrick Guirnalda; Peter Tsai; Matthew Seavey; Yvonne Paterson
Journal: Cancer Immunol Immunother Date: 2011-03-23 Impact factor: 6.968

6. A novel human Her-2/neu chimeric molecule expressed by Listeria monocytogenes can elicit potent HLA-A2 restricted CD8-positive T cell responses and impact the growth and spread of Her-2/neu-positive breast tumors.

Authors: Matthew M Seavey; Zhen-Kun Pan; Paulo C Maciag; Anu Wallecha; Sandra Rivera; Yvonne Paterson; Vafa Shahabi
Journal: Clin Cancer Res Date: 2009-02-01 Impact factor: 12.531

7. Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors.

Authors: Duane A Sewell; Zhen Kun Pan; Yvonne Paterson
Journal: Vaccine Date: 2008-08-03 Impact factor: 3.641

Review 8. Experimental vaccine strategies for cancer immunotherapy.

Authors: C H Chen; T C Wu
Journal: J Biomed Sci Date: 1998 Jul-Aug Impact factor: 8.410

9. Lm-LLO-Based Immunotherapies and HPV-Associated Disease.

Authors: Anu Wallecha; Chris French; Robert Petit; Reshma Singh; Ashok Amin; John Rothman
Journal: J Oncol Date: 2012-02-02 Impact factor: 4.375

10. Mage-b vaccine delivered by recombinant Listeria monocytogenes is highly effective against breast cancer metastases.

Authors: S H Kim; F Castro; D Gonzalez; P C Maciag; Y Paterson; C Gravekamp
Journal: Br J Cancer Date: 2008-08-19 Impact factor: 7.640

26 in total

1. Systemic listeriosis following vaccination with the attenuated Listeria monocytogenes therapeutic vaccine, ADXS11-001.

Authors: Joseph J Sacco; Mererid Evans; Kevin J Harrington; Stephen Man; Ned Powell; Richard J Shaw; Terry M Jones
Journal: Hum Vaccin Immunother Date: 2015-11-30 Impact factor: 3.452

2. Advances in bacterial cancer therapies using synthetic biology.

Authors: Tiffany Chien; Anjali Doshi; Tal Danino
Journal: Curr Opin Syst Biol Date: 2017-05-23

Review 3. Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine.

Authors: Dmitriy Zamarin; Amir A Jazaeri
Journal: Gynecol Oncol Date: 2016-04 Impact factor: 5.482

Review 4. Summary of emerging targets in anal cancer: the case for an immunotherapy based-approach.

Authors: Van Morris; Cathy Eng
Journal: J Gastrointest Oncol Date: 2016-10

Review 5. Human papillomavirus-driven immune deviation: challenge and novel opportunity for immunotherapy.

Authors: Sigrun Smola; Connie Trimble; Peter L Stern
Journal: Ther Adv Vaccines Date: 2017-07-05

Review 6. Targeting cellular and molecular drivers of head and neck squamous cell carcinoma: current options and emerging perspectives.

Authors: Simonetta Ausoni; Paolo Boscolo-Rizzo; Bhuvanesh Singh; Maria Cristina Da Mosto; Giacomo Spinato; Giancarlo Tirelli; Roberto Spinato; Giuseppe Azzarello
Journal: Cancer Metastasis Rev Date: 2016-09 Impact factor: 9.264

Review 7. Therapeutic cancer vaccines.

Authors: Cornelis J M Melief; Thorbald van Hall; Ramon Arens; Ferry Ossendorp; Sjoerd H van der Burg
Journal: J Clin Invest Date: 2015-07-27 Impact factor: 14.808